



Lilly to Participate in Guggenheim Biopharma Strategy Series

June 14, 2021

INDIANAPOLIS, June 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – on Friday, June 18, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific and Medical Officer and President of Lilly Research Laboratories, will participate in a virtual fireside chat at 11:00 a.m., Eastern Time.

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at <https://investor.lilly.com/webcasts-and-presentations>. A replay of the presentation will be available on this same website for approximately 90 days.

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/news. F-LLY



Refer to: Molly McCully; mccully_molly@lilly.com; 317-478-5423 (Media)
Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (Investors)

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/lilly-to-participate-in-guggenheim-biopharma-strategy-series-301311034.html>

SOURCE Eli Lilly and Company